Addex First Half 2009 Financial Results Tuesday, July 28
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Geneva, Switzerland, 23 July 2009 - Addex Pharmaceuticals Ltd.(SIX:ADXN) will discuss its financial results for the first half of2009 and reiterate the status of its pipeline during a teleconferenceand webcast for investors, analysts and the media on Tuesday, July 28at 16:00 CEST. Addex updated its pipeline status at its R&D Day onJuly 16. The slides and recorded webcasts from the R&D Day areavailable at www.addexpharma.com.Title: Addex First Half 2009 Financial Results Conference CallDate: 28 July 2008Time: 16:00 CESTDial-in numbers: +41 91 610 56 00 (Europe) +44 207 107 0611 (UK) +1 866 291 4166 (USA)The live webcast and slides, as well as the webcast replay andtranscript, will be available at www.addexpharma.com.Addex Pharmaceuticals (www.addexpharma.com) discovers and developsallosteric modulators for human health. Allosteric modulators are adifferent kind of orally available small molecule therapeutic agent,which we believe will offer a competitive advantage over classicaldrugs. Our lead allosteric modulator product, ADX10059, has achievedclinical proof of concept and is in Phase IIb testing in twoindications. Phase IIb data for ADX10059 to treat gastroesophagealreflux disease (GERD) are expected in the fourth quarter of 2009.Phase IIb data for ADX10059 as a migraine prevention therapy inpatients with frequent migraine are expected in the first quarter of2010. ADX10059 is a first-in-class mGluR5 inhibitor, a therapeuticstrategy that also is being pursued in multiple indications by largepharma competitors.Our products and technology already have proven their value throughour relationships with four of the top 10 pharmaceutical companies inthe world. Specifically, under an agreement with Ortho-McNeil-JanssenInc., a Johnson & Johnson company, ADX71149, a positive allostericmodulator (PAM) of mGluR2 with potential for the treatment ofschizophrenia and anxiety, is undergoing Phase I clinical testing.Under two separate agreements with Merck & Co., Inc., we aredeveloping mGluR4 PAM and mGluR5 PAM as drugs to treat Parkinson'sdisease and schizophrenia, respectively. In addition, GlaxoSmithKlineand Roche have made equity investments in Addex.Chris MaggosHead of IR & CommunicationsAddex Pharmaceuticals+41 22 884 15 11chris.maggos(at)addexpharma.comDisclaimer: The foregoing release may contain forward-lookingstatements that can be identified by terminology such as "notapprovable", "continue", "believes", "believe", "will", "remainedopen to exploring", "would", "could", or similar expressions, or byexpress or implied discussions regarding Addex Pharmaceuticals Ltd,its business, the potential approval of its products by regulatoryauthorities, or regarding potential future revenues from suchproducts. Such forward-looking statements reflect the current viewsof Addex Pharmaceuticals Ltd regarding future events, future economicperformance or prospects, and, by their very nature, involve inherentrisks and uncertainties, both general and specific, whether known orunknown, and/or any other factor that may materially differ from theplans, objectives, expectations, estimates and intentions expressedor implied in such forward-looking statements. Such may in particularcause actual results with allosteric modulators of mGluR2, mGluR4,mGluR5, mGluR7 or other therapeutic targets to be materiallydifferent from any future results, performance or achievementsexpressed or implied by such statements. There can be no guaranteethat allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 will beapproved for sale in any market or by any regulatory authority. Norcan there be any guarantee that allosteric modulators of mGluR2,mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve anyparticular levels of revenue (if any) in the future. In particular,management's expectations regarding allosteric modulators of mGluR2,mGluR4, mGluR5, mGluR7 or other therapeutic targets could be affectedby, among other things, unexpected actions by our partners,unexpected regulatory actions or delays or government regulationgenerally; unexpected clinical trial results, including unexpectednew clinical data and unexpected additional analysis of existingclinical data; competition in general; government, industry andgeneral public pricing pressures; the company's ability to obtain ormaintain patent or other proprietary intellectual propertyprotection. Should one or more of these risks or uncertaintiesmaterialize, or should underlying assumptions prove incorrect, actualresults may vary materially from those anticipated, believed,estimated or expected. Addex Pharmaceuticals Ltd is providing theinformation in this press release as of this date and does notundertake any obligation to update any forward-looking statementscontained in this press release as a result of new information,future events or otherwise, except as may be required by applicablelaws. --- End of Message ---Addex Pharmaceuticals12, chemin des Aulx Plan-les-Ouates, Geneva SwitzerlandISIN: CH0029850754; Index: SLIFE, SPI, SPIEX, SSCI;Listed: Main Market in SIX Swiss Exchange;
Datum: 23.07.2009 - 07:02 Uhr
Sprache: Deutsch
News-ID 3862
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 282 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex First Half 2009 Financial Results Tuesday, July 28"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
